Related Experiment Videos
Beta-blockers in congestive heart failure. A Bayesian meta-analysis
J M Brophy1, L Joseph, J L Rouleau
1Service de Cardiologie, Centre Hospitalier de l'Université de Montréal, Pavillon Notre-Dame, 1560 rue Sherbrooke Est, Montreal, Quebec H2L 4M1, Canada. jbroph@po-box.mcgill.ca
Annals of Internal Medicine
|April 3, 2001
Summary
Beta-blocker therapy significantly reduces mortality and hospitalizations in patients with congestive heart failure. This meta-analysis confirms beta-blockers offer substantial benefits, saving lives and reducing healthcare utilization.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Congestive heart failure (CHF) is a major cause of patient morbidity and mortality.
- Previous randomized clinical trials (RCTs) have investigated beta-blockers for CHF treatment.
- A recent meta-analysis was needed to quantify the impact of beta-blockers on CHF mortality and morbidity.
Purpose of the Study:
- To conduct a meta-analysis quantifying the effect of beta-blockers versus placebo on mortality and morbidity in chronic stable congestive heart failure.
- To synthesize evidence from RCTs to provide a robust estimate of beta-blocker efficacy in CHF.
Main Methods:
- Systematic search of MEDLINE, Cochrane, and Web of Science databases (1966-July 2000).
- Inclusion of all RCTs comparing beta-blockers with placebo in chronic stable CHF.
- Data extraction on patient characteristics, beta-blocker type, mortality, hospitalizations, and study quality using a standardized protocol.
Main Results:
- 22 trials with 10,135 patients were analyzed.
- Beta-blocker therapy was associated with a near 100% probability of reducing total mortality and CHF hospitalizations.
- Estimated benefits include 3.8 lives saved and 4 fewer hospitalizations per 100 patients treated in the first year, with 99% probability of clinical significance.
Conclusions:
- Beta-blocker therapy demonstrates clinically meaningful reductions in mortality and morbidity for stable CHF patients.
- Routine offering of beta-blocker therapy to eligible CHF patients is recommended.
- Both selective and nonselective beta-blockers showed positive effects, and results were robust to publication bias.